When will the PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE patents expire, and when will PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE go generic?

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Septodont Inc	PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE	epinephrine bitartrate; prilocaine hydrochloride	INJECTABLE;INJECTION	078959-001	Aug 30, 2011	AP	RX	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: July 26, 2026

Executive summary: Prilocaine hydrochloride and epinephrine bitartrate is a niche, procedure-linked branded/local-anesthetic combination used primarily in dental soft-tissue anesthesia. Commercial upside is tied to (1) reimbursement and utilization trends in outpatient dentistry, (2) generic penetration risk, and (3) any differentiation via delivery (cartridge/device), concentration, and packaging that can slow substitution. The patent and regulatory moat for this legacy combination is generally limited to formulation and device-specific remnants rather than long-running new chemical entity exclusivity, which shifts the investment thesis toward supply-chain execution, contracting, and defense of specific product configurations rather than expecting multi-year blockbusters.

What is prilocaine hydrochloride and epinephrine bitartrate used for in dentistry and how does it drive demand?

Primary use: Local anesthesia to provide pain control during dental procedures. The combination pairs prilocaine (local anesthetic) with epinephrine bitartrate (vasoconstrictor) to prolong anesthetic effect, reduce systemic absorption, and improve hemostasis at the injection site.

Where does revenue come from?

Demand is driven by:

Procedure volume in outpatient dentistry (routine fillings, extractions, periodontal work).
Product contracting with GPOs, DSOs, hospital dental clinics, and dental supply distributors.
Substitution dynamics after generic entry, which is common for established local anesthetic cartridges unless product form factors are defended.

What are the key demand risks?

High substitutability across generic local anesthetic cartridges.
Budget pressure in dental channels.
Utilization cyclicality (elective procedures can soften during downturns).
Formulation/device swaps that reduce brand advantage.

What patents protect prilocaine hydrochloride and epinephrine bitartrate and how strong is the patent estate?

Short answer: For older local anesthetic actives, patent protection is typically fragmented and often anchored in later patents on specific formulations, packaging, or manufacturing controls rather than composition-of-matter.

How patent strength usually maps to investability in this class

For legacy local anesthetic combinations, investors generally underwrite:

Whether any active patents still cover the specific marketed presentation (cartridge size, concentration, salt form, solvent system, preservatives).
Whether method-of-use claims exist for dental anesthesia protocols or timing regimens.
Manufacturing process claims that can block generic “work-alike” production.

What to underwrite in diligence

Even without assuming strong chemical-entitlement breadth, diligence should focus on:

Identification of Orange Book-listed patents (drug substance, drug product, and methods) tied to each NDA/ANDA presentation.
Whether patents are expiration-locked versus still in force due to late-filed continuations.
Whether any litigation exists that suggests non-trivial infringement risk for generics.

(Note: a complete, numbered patent list with expiration dates and assignees cannot be produced here because no Orange Book or patent-bibliographic dataset is provided in the prompt.)

What is the Orange Book status of Prilocaine HCl and Epinephrine bitartrate products and how does it affect generic entry timing?

Short answer: In legacy local anesthetic combinations, Orange Book listings are often limited; if remaining drug product or method patents are sparse, generic competition can accelerate as soon as regulatory exclusivities and listed patents expire.

What Orange Book entries typically matter

Drug substance patents: generally expired long ago for older actives.
Drug product patents: can cover formulation details or stability.
Method-of-use patents: can delay certain carve-outs if the generic is forced to label differently.

How to convert Orange Book into an entry forecast

A generic launch risk model typically uses:

Earliest patent expiration for listed blocking patents.
Exclusivity overlays (e.g., if any marketing exclusivity still applies, which is uncommon this far out for old local anesthetics).
PIV/Paragraph IV strategy likelihood once patents are identified.

When does exclusivity end for prilocaine hydrochloride and epinephrine bitartrate and what are the generic launch scenarios?

Short answer: The most probable launch scenario is multiple generic entries after the last relevant patent block clears (often with rapid price erosion), with the best-case outcome for investors limited to specific presentations that retain formulation/device protection.

Scenario framework used by commercial investors

Base case: Generic entry occurs at or soon after the last meaningful listed patent expiration; brand share declines over 6 to 18 months.
Downside case: Faster entry due to carve-outs or because blocking patents are invalidated/settled.
Upside case: Litigation settlement delays entry; fewer SKUs are easily substitutable; customer switching requires re-education or contracts.

Which companies hold the marketed products for this combination and how does competitive positioning shape margins?

Short answer: Competition in local anesthetics usually includes:

Branded incumbent distributors.
Multiple generic manufacturers producing cartridge presentations.
Channel power from distributors and purchasing groups that enforce price.

What matters for profitability

Net price realization versus headline WAC list price.
Manufacturing scale and yield for cartridge filling and sterilization steps.
Slotting and contracting costs in dental channels.
Freight and cold-chain needs (often minimal for local anesthetic cartridges, but packaging and stability still matter).

(No manufacturer-specific ranking can be supplied without the exact NDA/marketed labels and Orange Book dataset.)

What formulation, packaging, or device patents can protect prilocaine-epinephrine cartridge performance?

Short answer: In practice, residual protection is most often found in:

Formulation details (pH range, antioxidant/stability system, preservative choices).
Concentration and salt-state combinations that affect shelf-life.
Packaging configurations (cartridge volume, needle compatibility, blister/overwrap).
Manufacturing process parameters that improve stability or reduce impurity formation.

Key technical discriminators to diligence

Stability and shelf-life claims on accelerated/real-time data.
Preservative and antioxidant system and how it maps to impurity specs.
Targeted viscosity and injection experience metrics, where regulators approve.

How do Paragraph IV challenges and patent settlements typically unfold for local anesthetic combinations?

Short answer: For mature injectables, Paragraph IV filings are usually used to:

Trigger a 30-month stay if a lawsuit is filed.
Negotiate settlements that buy a delay in entry.
Reduce litigation exposure via non-infringement or invalidity positions.

What settlement terms change the investment case

Date-specific entry obligations (e.g., delayed generic launch).
SKU limits (one dosage strength only, or one packaging format).
Label carve-outs that avoid method-of-use claims.
Co-marketing or supply agreements that cap downside.

(No specific court dates or settlement terms can be enumerated without litigation docket inputs.)

What patent litigation affects prilocaine hydrochloride and epinephrine bitartrate?

Short answer: Patent litigation in this class, where it exists, usually centers on:

Drug product formulation or manufacturing claims.
Orange Book method-of-use claims, if present.
Cartridge/packaging claims tied to approved label presentations.

How litigation impacts valuation

Probability-weighted entry dates based on stay duration and settlement outcomes.
Legal cost and duration risk for the claimant.
Reputational and distributor uncertainty during court proceedings.

(No case-level data is supplied in the prompt, so no litigation list or outcomes can be generated.)

What regulatory pathway governs generic versions and what FDA labeling constraints matter?

Short answer: Generics typically pursue an ANDA referencing an approved local anesthetic combination drug. The main gating issues are:

Bioequivalence (for locally acting drugs, regulators still apply standard BE and PK requirements for injectables where applicable).
Labeling consistency with approved indications and concentrations.
Impurity profile and stability alignment with reference products.

What labeling constraints typically affect substitution

Exact concentration and active ingredient salt state.
Whether warnings or contraindications differ across versions.
Any method-of-use framing differences that influence switch behavior in clinics.

How does prilocaine with epinephrine compare with lidocaine with epinephrine for clinical and commercial competitiveness?

Short answer: Both are common dental local anesthetic combinations. Commercial differentiation typically comes less from “clinical superiority” and more from:

price and contracting,
switching friction in practice,
availability of preferred cartridges,
and any label nuance that impacts clinicians’ choice.

Investment implications of class competition

If the incumbent is not clearly differentiated, generic substitution pressure is high and margin compression is expected. In practice, the investor thesis leans on:

manufacturing unit cost reduction,
high fill-rate distribution contracts,
and minimizing SKU rationalization risk during competitive launches.

(No head-to-head clinical effect sizes are provided in the prompt; this section therefore focuses on commercialization mechanics rather than efficacy claims.)

Revenue exposure model: what drives unit volume and pricing for this drug category?

Short answer: Unit demand is tied to dental procedure volume and clinician habit; pricing is driven by generic competitive dynamics and distributor contract terms.

Key KPIs to underwrite

TRx or units per quarter by strength and package size.
Channel mix: dental wholesalers vs direct group purchasing.
Net price trends versus WAC.
Distribution coverage: number of stocking accounts in top dental networks.
Loss rate after generic entry (time to share decline).

What margin structure depends on

Fill-finish and cartridge manufacturing yield.
Packaging and labeling compliance cost.
Inventory carrying costs under shelf-life constraints.

What manufacturing and IP barriers protect incumbents, and what production risks can break margins?

Short answer: For cartridge injectables, the durable barrier is often execution quality:

consistent impurity control,
stability at label shelf-life,
and reliable sterilization and sealing.

Operational diligence targets

Container-closure integrity testing regime.
Stability test results for epinephrine sensitivity and preservative system robustness.
Scale economics for cartridge filling and labeling lines.
Supply continuity for active ingredients and excipients.

Commercial entry strategies: how do investors underwrite buy-in versus build-out?

Licensing (buy-in)

Works when a target holds a defensible branded SKU, contract position, or device/package advantage.
Risks: contracts roll off; generic competition reduces exclusivity beyond the licensing horizon.

Build-out (manufacturing and ANDA)

Works when the unit economics allow margin after generic price compression.
Risks: formulation stability issues and regulatory delays can erase the expected launch window.

Key Takeaways

Prilocaine hydrochloride and epinephrine bitartrate is a demand-linked, outpatient procedure product where commercial upside depends on contracting, distribution reach, and resistance to substitution rather than long-duration chemical monopolies.
The likely patent moat (if any) is concentrated in specific drug product presentation, formulation stability details, packaging, or manufacturing controls rather than broad composition-of-matter.
Investment value is most sensitive to (1) Orange Book blocking patent inventory tied to the exact marketed presentation and (2) the timing of generic entry and any Paragraph IV litigation or settlement delays.
Fundamentals should be underwritten on unit-volume drivers in dental channels, net price realization under generic competition, and execution quality in cartridge manufacturing and stability assurance.

FAQs

How do generics of local anesthetic cartridges typically win share after Orange Book expiration?
By offering equivalent concentration/labeling and matching packaging formats that minimize switching friction, then relying on distribution contracting to drive net price.
What formulation attributes most affect epinephrine stability in injectable local anesthetics?
Preservative/antioxidant selection, pH targeting, container-closure integrity, and validated stability under real-time and accelerated conditions.
Can method-of-use patents delay generic entry for dental local anesthetics?
Only if such patents are listed in the Orange Book for the specific NDA presentation and the generic’s label/use is constrained by infringement risk or settlement terms.
What dosing and labeling differences most influence dental clinician substitution decisions?
Concentration and cartridge volume, warning language, and any label nuances tied to contraindications or administration guidance.
What diligence items best predict whether an ANDA for this combination will face approval or manufacturing delays?
Stability alignment, impurity control strategy, and container-closure integrity performance for epinephrine-containing injectables.

References (APA)

FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed via FDA Orange Book database).
FDA Guidance for Industry: Bioequivalence Studies Submitted in NDAs or INDAs: General Considerations. U.S. Food and Drug Administration. (Accessed via FDA guidance library).

US Patents:	0
Applicants:	1
NDAs:	1

AI Deep Research

Questions you can ask:

Summary for PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE